Patterns of use and safety of ibrutinib in real‐life practice

Cohort study (n=102) found high cumulative incidence of ibrutinib‐associated serious ADRs (SADR) within 1st year of treatment (47.1% had ≥1 SADR). Age ≥80 years (HR 2.03; 95% CI 1.02–4.05) and CLL (1.81; 1.01–3.25) were significantly linked to higher risk of SADR occurrence.

Source:

British Journal of Clinical Pharmacology